Skip to search formSkip to main contentSkip to account menu

Zinplava

National Institutes of Health

Related topics

Related topics

2 relations
40 ML bezlotoxumab 25 MG/ML Injection [Zinplava]

Broader (1)

bezlotoxumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
[Preclinical and clinical properties of Bezlotoxumab (ZINPLAVA® 25 mg/mL concentrate for solution for infusion), novel therapeutic agent for Clostridium difficile infection].
  • K. Kinoshita
  • Nihon yakurigaku zasshi. Folia pharmacologica…
  • 2018
  • Corpus ID: 51616453
Clostridium difficile (C. difficile), an enterobacteria, flourishes and produces potent toxins, toxin A (TcdA) and toxin B (TcdB… 
2017
2017
Bezlotoxumab (Zinplava) for Clostridium Difficile Infection: The First Monoclonal Antibody Approved to Prevent the Recurrence of a Bacterial Infection.
Bezlotoxumab (Zinplava) to prevent the recurrence of Clostridium difficile infection. 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)